CannBioRx Historical Income Statement

ATNFW Stock

USD 0.01 0 22.22%

Historical analysis of CannBioRx Life income statement accounts such as Selling General Administrative of 7.6 M, Interest Income of 0.0 or Other Operating Expenses of 18.7 M can show how well CannBioRx Life Sciences performed in making a profits. Evaluating CannBioRx Life income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CannBioRx Life's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining CannBioRx Life Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CannBioRx Life Sciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CannBioRx Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

About CannBioRx Income Statement Analysis

CannBioRx Life Sciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CannBioRx Life shareholders. The income statement also shows CannBioRx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

CannBioRx Life Income Statement Chart

At this time, CannBioRx Life's Other Operating Expenses is fairly stable compared to the past year. Total Operating Expenses is likely to climb to about 18.7 M in 2024, whereas Selling General Administrative is likely to drop slightly above 7.6 M in 2024.

Net Income Other Operating Expenses Total Operating Expenses Research Development

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in CannBioRx Life Sciences financial statement analysis. It represents the amount of money remaining after all of CannBioRx Life Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CannBioRx Life Sciences. It is also known as CannBioRx Life overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from CannBioRx Life's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CannBioRx Life Sciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CannBioRx Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

	2021	2022	2023	2024 (projected)
Research Development	3.9M	2.4M	2.8M	2.7M
Depreciation And Amortization	116.3K	109.0K	105.7K	101.1K

Research Development Depreciation And Amortization

CannBioRx Life income statement Correlations

	Selling General Administrative	Operating Income	Income Before Tax	Net Income	Tax Provision	Interest Income	Other Operating Expenses	Ebit	Ebitda	Total Operating Expenses	Total Other Income Expense Net	Income Tax Expense	Depreciation And Amortization	Research Development	Net Interest Income	Selling And Marketing Expenses	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Reconciled Depreciation
Selling General Administrative		-0.89	-0.95	-0.94	-0.53	-0.32	0.92	-0.87	-0.87	0.92	-0.9	-0.28	0.78	0.8	0.21	0.67	-0.74	-0.48	0.74	0.69
Operating Income	-0.89		0.95	0.96	0.48	0.17	-0.93	0.96	0.96	-0.93	0.78	0.33	-0.77	-0.79	-0.16	-0.56	0.62	0.4	-0.62	-0.59
Income Before Tax	-0.95	0.95		1.0	0.54	0.25	-0.98	0.91	0.91	-0.98	0.93	0.27	-0.79	-0.75	-0.17	-0.69	0.69	0.5	-0.69	-0.66
Net Income	-0.94	0.96	1.0		0.49	0.22	-0.98	0.9	0.9	-0.98	0.92	0.23	-0.79	-0.74	-0.15	-0.65	0.67	0.47	-0.67	-0.64
Tax Provision	-0.53	0.48	0.54	0.49		0.59	-0.39	0.68	0.68	-0.39	0.55	0.88	-0.58	-0.55	-0.28	-0.94	0.61	0.79	-0.61	-0.71
Interest Income	-0.32	0.17	0.25	0.22	0.59		-0.2	0.3	0.3	-0.2	0.31	0.34	-0.41	-0.51	-0.38	-0.6	0.51	0.54	-0.51	-0.49
Other Operating Expenses	0.92	-0.93	-0.98	-0.98	-0.39	-0.2		-0.84	-0.84	1.0	-0.91	-0.1	0.69	0.67	0.23	0.58	-0.58	-0.46	0.58	0.52
Ebit	-0.87	0.96	0.91	0.9	0.68	0.3	-0.84		1.0	-0.84	0.75	0.56	-0.85	-0.87	-0.12	-0.69	0.75	0.47	-0.75	-0.75
Ebitda	-0.87	0.96	0.91	0.9	0.68	0.3	-0.84	1.0		-0.84	0.74	0.56	-0.85	-0.87	-0.12	-0.69	0.75	0.47	-0.75	-0.74
Total Operating Expenses	0.92	-0.93	-0.98	-0.98	-0.39	-0.2	1.0	-0.84	-0.84		-0.91	-0.1	0.69	0.67	0.23	0.58	-0.58	-0.46	0.58	0.52
Total Other Income Expense Net	-0.9	0.78	0.93	0.92	0.55	0.31	-0.91	0.75	0.74	-0.91		0.18	-0.73	-0.6	-0.13	-0.76	0.69	0.56	-0.69	-0.68
Income Tax Expense	-0.28	0.33	0.27	0.23	0.88	0.34	-0.1	0.56	0.56	-0.1	0.18		-0.4	-0.43	-0.17	-0.68	0.42	0.57	-0.42	-0.54
Depreciation And Amortization	0.78	-0.77	-0.79	-0.79	-0.58	-0.41	0.69	-0.85	-0.85	0.69	-0.73	-0.4		0.92	-0.28	0.59	-0.95	-0.19	0.95	0.94
Research Development	0.8	-0.79	-0.75	-0.74	-0.55	-0.51	0.67	-0.87	-0.87	0.67	-0.6	-0.43	0.92		-0.04	0.52	-0.89	-0.22	0.89	0.84
Net Interest Income	0.21	-0.16	-0.17	-0.15	-0.28	-0.38	0.23	-0.12	-0.12	0.23	-0.13	-0.17	-0.28	-0.04		0.36	0.27	-0.74	-0.27	-0.29
Selling And Marketing Expenses	0.67	-0.56	-0.69	-0.65	-0.94	-0.6	0.58	-0.69	-0.69	0.58	-0.76	-0.68	0.59	0.52	0.36		-0.62	-0.88	0.62	0.69
Gross Profit	-0.74	0.62	0.69	0.67	0.61	0.51	-0.58	0.75	0.75	-0.58	0.69	0.42	-0.95	-0.89	0.27	-0.62		0.21	-1.0	-0.98
Net Income From Continuing Ops	-0.48	0.4	0.5	0.47	0.79	0.54	-0.46	0.47	0.47	-0.46	0.56	0.57	-0.19	-0.22	-0.74	-0.88	0.21		-0.21	-0.27
Cost Of Revenue	0.74	-0.62	-0.69	-0.67	-0.61	-0.51	0.58	-0.75	-0.75	0.58	-0.69	-0.42	0.95	0.89	-0.27	0.62	-1.0	-0.21		0.98
Reconciled Depreciation	0.69	-0.59	-0.66	-0.64	-0.71	-0.49	0.52	-0.75	-0.74	0.52	-0.68	-0.54	0.94	0.84	-0.29	0.69	-0.98	-0.27	0.98

Click cells to compare fundamentals

CannBioRx Life Account Relationship Matchups

CannBioRx Life income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	185.1K	1.1M	186.2K	26.7K	44.83	42.59
Selling General Administrative	5.9M	3.4M	11.7M	15.5M	10.7M	7.6M
Operating Income	(20.9M)	(5.6M)	(15.6M)	(17.9M)	(13.5M)	(14.2M)
Income Before Tax	(25.4M)	(10.9M)	(20.3M)	(39.7M)	(22.3M)	(23.4M)
Net Income	(25.4M)	(10.9M)	(20.3M)	(38.7M)	(19.9M)	(20.9M)
Tax Provision	257.3K	(20.4K)	(23.2K)	(942.7K)	(3.3M)	(3.1M)
Other Operating Expenses	25.2M	5.6M	20.2M	39.6M	13.5M	18.7M
Ebit	(20.9M)	(9.8M)	(20.2M)	(17.9M)	(22.2M)	(23.4M)
Ebitda	(20.8M)	(9.7M)	(20.0M)	(17.8M)	(22.1M)	(23.2M)
Total Operating Expenses	25.2M	5.6M	20.2M	39.6M	13.5M	18.7M
Total Other Income Expense Net	(4.5M)	(5.3M)	(4.7M)	(21.8M)	(8.8M)	(9.2M)
Income Tax Expense	9.5K	(20.4K)	23.2K	942.7K	(2.3M)	(2.2M)
Depreciation And Amortization	72.2K	125.3K	116.3K	109.0K	105.7K	101.1K
Research Development	2.0M	2.3M	3.9M	2.4M	2.8M	2.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for CannBioRx Stock Analysis

When running CannBioRx Life's price analysis, check to measure CannBioRx Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CannBioRx Life is operating at the current time. Most of CannBioRx Life's value examination focuses on studying past and present price action to predict the probability of CannBioRx Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CannBioRx Life's price. Additionally, you may evaluate how the addition of CannBioRx Life to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CannBioRx Historical Income Statement

About CannBioRx Income Statement Analysis

CannBioRx Life Income Statement Chart

Net Income

Other Operating Expenses

Total Operating Expenses

CannBioRx Life income statement Correlations

CannBioRx Life Account Relationship Matchups

High Positive Relationship

High Negative Relationship

CannBioRx Life income statement Accounts

Also Currently Popular

Additional Tools for CannBioRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 1.0	Income Before Tax
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Reconciled Depreciation	+ 0.98	Cost Of Revenue
Net Income	+ 0.96	Operating Income
Ebit	+ 0.96	Operating Income

Cost Of Revenue	- 1.0	Gross Profit
Reconciled Depreciation	- 0.98	Gross Profit
Total Operating Expenses	- 0.98	Net Income
Other Operating Expenses	- 0.98	Net Income
Total Operating Expenses	- 0.98	Income Before Tax
Other Operating Expenses	- 0.98	Income Before Tax